ReviewMovement disorders : official journal of the Movement Disorder Society2017
Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?
Review in Movement disorders : official journal of the Movement Disorder Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 140 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
140 citing papers in PubMed, 4 syntheses or guidelines pooled it, 250 citations in OpenAlex.
- Differentiating progressive supranuclear palsy from other movement disorders using transcranial sonography: a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Pooled it
- Pooled it
- Atrophy in midbrain & cerebral/cerebellar pedunculi is characteristic for progressive supranuclear palsy - A double-validation whole-brain meta-analysis.NeuroImage. Clinical · 2019Pooled it
- Which ante mortem clinical features predict progressive supranuclear palsy pathology?Movement disorders : official journal of the Movement Disorder Society · 2017Pooled it
- Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.Nature medicine · 2021Trial
- Multimodal neuroimaging in dementia and neurodegenerative disorders: complementary roles of clinically available nuclear medicine and MRI in the era of disease-modifying therapies.Japanese journal of radiology · 2026Review
- The swallow tail sign: mechanisms, neuroimaging advances and future perspectives.Insights into imaging · 2026Article
- A Brainstem Radiomics Framework to Distinguish Progressive Supranuclear Palsy from Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- Remote network for cognitive symptoms derived from tau accumulation in progressive supranuclear palsy.Science advances · 2026Article
- Brainstem and Cerebellar Volume Loss and Associated Clinical Features in Progressive Supranuclear Palsy.Annals of clinical and translational neurology · 2026Observational
- Fluid Biomarkers of Disease Burden and Cognitive Dysfunction in Progressive Supranuclear Palsy.Annals of clinical and translational neurology · 2026Article
- Unilateral inferior olivary hypertrophy in a patient with primary progressive apraxia of speech.Neuroimage. Reports · 2026Article
- Localized Iron Deposition and Shape Changes of Cerebellar Dentate in Progressive Supranuclear Palsy Clinical Variants.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- Article
- Altered astrocyte-neuron crosstalk in progressive supranuclear palsy: integrated evidence from proteomics and magnetic resonance spectroscopy.Acta neuropathologica · 2026Article
- Dementia in Progressive Supranuclear Palsy: A Narrative Review.Neurology and therapy · 2026Review
- Subtracting First Principal Component May Improve 4R Tau Detectability on [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Quantitative Susceptibility Mapping and Iron Deposition in Autopsy-Confirmed Progressive Supranuclear Palsy.Movement disorders clinical practice · 2026Article
- Multi-model Diffusion MRI Signatures in Atypical Parkinsonian Disorders.medRxiv : the preprint server for health sciences · 2026Article
- Patterns of Longitudinal Regional Brain Atrophy in Patients With Different Progressive Supranuclear Palsy Clinical Variants.Neurology · 2025Article
80 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 13 institutions in 5 countries.
Funding
Abstract
PSP is a pathologically defined neurodegenerative tauopathy with a variety of clinical presentations including typical Richardson's syndrome and other variant PSP syndromes. A large body of neuroimaging research has been conducted over the past two decades, with many studies proposing different structural MRI and molecular PET/SPECT biomarkers for PSP. These include measures of brainstem, cortical and striatal atrophy, diffusion weighted and diffusion tensor imaging abnormalities, [18F] fluorodeoxyglucose PET hypometabolism, reductions in striatal dopamine imaging and, most recently, PET imaging with ligands that bind to tau. Our aim was to critically evaluate the degree to which structural and molecular neuroimaging metrics fulfill criteria for diagnostic biomarkers of PSP. We queried the PubMed, Cochrane, Medline, and PSYCInfo databases for original research articles published in English over the past 20 years using postmortem diagnosis or the NINDS-SPSP criteria as the diagnostic standard from 1996 to 2016. We define a five-level theoretical construct for the utility of neuroimaging biomarkers in PSP, with level 1 representing group-level findings, level 2 representing biomarkers with demonstrable individual-level diagnostic utility, level 3 representing biomarkers for early disease, level 4 representing surrogate biomarkers of PSP pathology, and level 5 representing definitive PSP biomarkers of PSP pathology. We discuss the degree to which each of the currently available biomarkers fit into this theoretical construct, consider the role of biomarkers in the diagnosis of Richardson's syndrome, variant PSP syndromes and autopsy confirmed PSP, and emphasize current shortfalls in the field. © 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.